Geospatial Disparities in the Treatment of Curable Breast Cancer Across the US. JAMA Oncol. 2022 03 01; 8(3):445-449.
View in:
PubMed
Global challenges and policy solutions in breast cancer control. Cancer Treat Rev. 2022 Mar; 104:102339.
View in:
PubMed
Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort. JCO Precis Oncol. 2022 01; 6:e2100232.
View in:
PubMed
eSyM: An Electronic Health Record-Integrated Patient-Reported Outcomes-Based Cancer Symptom Management Program Used by Six Diverse Health Systems. JCO Clin Cancer Inform. 2022 Jan; 6:e2100137.
View in:
PubMed
Correction to: Time-Driven Activity-Based Costing in Breast Cancer Care Delivery. Ann Surg Oncol. 2021 Dec; 28(Suppl 3):899.
View in:
PubMed
ASO Visual Abstract: Time-Driven Activity-Based Costing (TDABC) in Breast Cancer Care Delivery. Ann Surg Oncol. 2021 Dec; 28(Suppl 3):599-600.
View in:
PubMed
Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 11; 26(11):927-933.
View in:
PubMed
Patterns of Medical Care Cost by Service Type for Patients With Recurrent and De Novo Advanced Cancer. Value Health. 2022 01; 25(1):69-76.
View in:
PubMed
Regarding the Utility of Unstructured Data and Natural Language Processing for Identification of Breast Cancer Recurrence. JCO Clin Cancer Inform. 2021 09; 5:1024-1025.
View in:
PubMed
Time-Driven Activity-Based Costing in Breast Cancer Care Delivery. Ann Surg Oncol. 2022 Jan; 29(1):510-521.
View in:
PubMed
Correction to: Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):305.
View in:
PubMed
Clinical Inflection Point Detection on the Basis of EHR Data to Identify Clinical Trial-Ready Patients With Cancer. JCO Clin Cancer Inform. 2021 06; 5:622-630.
View in:
PubMed
Artificial intelligence in oncology: Path to implementation. Cancer Med. 2021 06; 10(12):4138-4149.
View in:
PubMed
Landscape Analysis of Oncology Mobile Health Applications. JCO Clin Cancer Inform. 2021 05; 5:579-587.
View in:
PubMed
Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):203-212.
View in:
PubMed
Population-based estimates of survival among elderly patients with brain metastases. Neuro Oncol. 2021 04 12; 23(4):661-676.
View in:
PubMed
Leveraging mobile health technology and research methodology to optimize patient education and self-management support for advanced cancer pain. Support Care Cancer. 2021 Oct; 29(10):5741-5751.
View in:
PubMed
Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. J Natl Compr Canc Netw. 2021 03 10; 19(7):797-804.
View in:
PubMed
Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Res Treat. 2021 Jun; 187(3):843-852.
View in:
PubMed
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021 02 20; 39(6):685-693.
View in:
PubMed
Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology. Clin Trials. 2020 12; 17(6):597-606.
View in:
PubMed
Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer. Radiat Oncol. 2020 Aug 17; 15(1):198.
View in:
PubMed
Natural Language Processing to Ascertain Cancer Outcomes From Medical Oncologist Notes. JCO Clin Cancer Inform. 2020 08; 4:680-690.
View in:
PubMed
Assessment of Temporal Selection Bias in Genomic Testing in a Cohort of Patients With Cancer. JAMA Netw Open. 2020 06 01; 3(6):e206976.
View in:
PubMed
Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. J Clin Oncol. 2020 07 20; 38(21):2390-2397.
View in:
PubMed
Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes. Breast Cancer Res Treat. 2020 May; 181(1):43-51.
View in:
PubMed
Management of Male Breast Cancer: ASCO Guideline Summary. JCO Oncol Pract. 2020 08; 16(8):e839-e843.
View in:
PubMed
Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol. 2020 06 01; 38(16):1849-1863.
View in:
PubMed
Commentary: Creating a patient-centered decision aid for ductal carcinoma in situ. Breast J. 2020 07; 26(7):1498-1499.
View in:
PubMed
Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era. Cancer Med. 2020 03; 9(6):2019-2029.
View in:
PubMed
Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. Cancer Discov. 2020 04; 10(4):526-535.
View in:
PubMed
Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes. Oncologist. 2020 02; 25(2):91-93.
View in:
PubMed
Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes. Oncologist. 2019 Nov 19.
View in:
PubMed
Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports. JAMA Oncol. 2019 Oct 01; 5(10):1421-1429.
View in:
PubMed
Spending for Advanced Cancer Diagnoses: Comparing Recurrent Versus De Novo Stage IV Disease. J Oncol Pract. 2019 07; 15(7):e616-e627.
View in:
PubMed
Performance of Cancer Recurrence Algorithms After Coding Scheme Switch From International Classification of Diseases 9th Revision to International Classification of Diseases 10th Revision. JCO Clin Cancer Inform. 2019 03; 3:1-9.
View in:
PubMed
Determining the Time of Cancer Recurrence Using Claims or Electronic Medical Record Data. JCO Clin Cancer Inform. 2018 12; 2:1-10.
View in:
PubMed
What drives variation in spending for breast cancer patients within geographic regions? Health Serv Res. 2019 02; 54(1):97-105.
View in:
PubMed
Use of Patient-Reported Outcome Measures in Quality Oncology Practice Initiative-Registered Practices: Results of a National Survey. J Oncol Pract. 2018 10; 14(10):e602-e611.
View in:
PubMed
How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated? Oncologist. 2019 07; 24(7):867-871.
View in:
PubMed
Increasing Burden of Prior Authorizations in the Delivery of Oncology Care in the United States. J Oncol Pract. 2018 09; 14(9):525-528.
View in:
PubMed
Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis. Health Serv Res. 2018 12; 53(6):5106-5128.
View in:
PubMed
Comparing Survival After Recurrent vs De Novo Stage IV Advanced Breast, Lung, and Colorectal Cancer. JNCI Cancer Spectr. 2018 Apr; 2(2):pky024.
View in:
PubMed
Estrogen-receptor status and risk of contralateral breast cancer following DCIS. Breast Cancer Res Treat. 2018 Oct; 171(3):777-781.
View in:
PubMed
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018 08 10; 36(23):2433-2443.
View in:
PubMed
Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ. J Natl Compr Canc Netw. 2018 04; 16(4):387-394.
View in:
PubMed
Chemotherapy medication errors. Lancet Oncol. 2018 04; 19(4):e191-e199.
View in:
PubMed
Development, Validation, and Dissemination of a Breast Cancer Recurrence Detection and Timing Informatics Algorithm. J Natl Cancer Inst. 2018 03 01; 110(3):273-281.
View in:
PubMed
Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer. JAMA. 2018 01 16; 319(3):306.
View in:
PubMed
Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Res Treat. 2018 Apr; 168(3):727-737.
View in:
PubMed
Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management. Med Care. 2017 12; 55(12):e88-e98.
View in:
PubMed
Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. Breast Cancer Res Treat. 2018 02; 167(3):751-759.
View in:
PubMed
Usability Considerations in Oncology Electronic Medical Records. J Oncol Pract. 2017 08; 13(8):539-541.
View in:
PubMed
Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death. Health Serv Res. 2018 08; 53(4):2118-2132.
View in:
PubMed
Quality Improvement in the Era of Big Data. J Clin Oncol. 2017 10 01; 35(28):3178-3180.
View in:
PubMed
Survival after recurrence of stage I-III breast, colorectal, or lung cancer. Cancer Epidemiol. 2017 08; 49:186-194.
View in:
PubMed
Implementation of the 21-gene recurrence score test in the United States in 2011. Genet Med. 2016 10; 18(10):982-90.
View in:
PubMed
Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Res Treat. 2016 Feb; 155(3):569-78.
View in:
PubMed
Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community. Breast Cancer Res Treat. 2016 Feb; 155(3):541-9.
View in:
PubMed
Challenges and Opportunities in Delivering High-Quality Cancer Care: A 2016 Update. Am Soc Clin Oncol Educ Book. 2016; 35:e294-300.
View in:
PubMed
Variation in breast cancer care quality in New York and California based on race/ethnicity and Medicaid enrollment. Cancer. 2016 Feb 01; 122(3):420-31.
View in:
PubMed
Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management. Med Care. 2015 Jul 29.
View in:
PubMed
Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. Int J Radiat Oncol Biol Phys. 2015 Nov 01; 93(3):622-30.
View in:
PubMed
Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer. 2015 Jun 15; 121(12):1937-48.
View in:
PubMed
Acute hospital care is the chief driver of regional spending variation in Medicare patients with advanced cancer. Health Aff (Millwood). 2014 Oct; 33(10):1793-800.
View in:
PubMed
Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2014 Oct; 52(10):e65-73.
View in:
PubMed
The relationship between quality, spending and outcomes among women with breast cancer. J Natl Cancer Inst. 2014 Oct; 106(10).
View in:
PubMed
High-priority topics for cancer quality measure development: results of the 2012 American Society of Clinical Oncology Collaborative Cancer Measure Summit. J Oncol Pract. 2014 May; 10(3):e160-6.
View in:
PubMed
Implementation of chemotherapy treatment plans (CTP) in a large comprehensive cancer center (CCC): The key roles of infrastructure and data sharing. J Clin Oncol. 2013 Nov; 31(31_suppl):20.
View in:
PubMed
Utilization of cardiac monitoring tests in women with nonmetastatic breast cancer treated with trastuzumab. Per Med. 2013 Sep; 10(7):703-708.
View in:
PubMed
What does breast cancer treatment cost and what is it worth? Hematol Oncol Clin North Am. 2013 Aug; 27(4):829-41, ix.
View in:
PubMed
Do drug interaction alerts between a chemotherapy order-entry system and an electronic medical record affect clinician behavior? J Oncol Pharm Pract. 2014 Jun; 20(3):163-71.
View in:
PubMed
Modeling the effectiveness of initial management strategies for ductal carcinoma in situ. J Natl Cancer Inst. 2013 Jun 05; 105(11):774-81.
View in:
PubMed
Regional variation in spending and survival for older adults with advanced cancer. J Natl Cancer Inst. 2013 May 01; 105(9):634-42.
View in:
PubMed
Cost of cancer care: The impact of disclosure on willingness to pay and treatment preferences. J Clin Oncol. 2012 Dec; 30(34_suppl):15.
View in:
PubMed
Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions. Cancer. 2013 Mar 01; 119(5):1065-72.
View in:
PubMed
Improving electronic oral chemotherapy prescription: can we build a safer system? J Oncol Pract. 2012 Nov; 8(6):e168-73.
View in:
PubMed
Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. J Natl Cancer Inst. 2012 Jul 18; 104(14):1102-5.
View in:
PubMed
Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer. 2012 Dec 15; 118(24):6022-30.
View in:
PubMed
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol. 2012 Jun 20; 30(18):2218-26.
View in:
PubMed
US Cancer Center Implementation of ASCO/Oncology Nursing Society Chemotherapy Administration Safety Standards. J Oncol Pract. 2012 Jan; 8(1):7-12.
View in:
PubMed
Identifying women at risk of delayed breast cancer diagnosis. Jt Comm J Qual Patient Saf. 2011 Dec; 37(12):568-75.
View in:
PubMed
Use of annual mammography among older women with ductal carcinoma in situ. J Gen Intern Med. 2012 May; 27(5):500-5.
View in:
PubMed
Economic evaluation of targeted cancer interventions: critical review and recommendations. Genet Med. 2011 Oct; 13(10):853-60.
View in:
PubMed
Relative dose intensity (RDI) assessment in an academic center. J Clin Oncol. 2011 Sep 20; 29(27_suppl):139.
View in:
PubMed
Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Res Treat. 2011 Nov; 130(2):619-26.
View in:
PubMed
Adjuvant hormone therapy use in early-stage breast cancer patients insured by the New York State Medicaid program. J Clin Oncol. 2011 May 20; 29(15_suppl):6031.
View in:
PubMed
The relationship between cost, quality, and outcomes among women with breast cancer in SEER-Medicare. J Clin Oncol. 2011 May 20; 29(15_suppl):6001.
View in:
PubMed
Pathologic characteristics of second breast cancers (SBC) among women previously treated for ductal carcinoma in situ (DCIS) with breast conservation. J Clin Oncol. 2011 May 20; 29(15_suppl):1042.
View in:
PubMed
Genomic testing and therapies for breast cancer in clinical practice. J Oncol Pract. 2011 May; 7(3 Suppl):e1s-7s.
View in:
PubMed
Genomic testing and therapies for breast cancer in clinical practice. Am J Manag Care. 2011 May 01; 17(5 Spec No):e174-81.
View in:
PubMed
Chemotherapy-related hospitalization among community cancer center patients. Oncologist. 2011; 16(3):378-87.
View in:
PubMed
Impact of neoadjuvant chemotherapy on breast reconstruction. Cancer. 2011 Jul 01; 117(13):2833-41.
View in:
PubMed
Using lifetime risk estimates to recommend magnetic resonance imaging screening for breast cancer survivors. J Clin Oncol. 2010 Sep 20; 28(27):4108-10.
View in:
PubMed
The full burden of cancer. Oncologist. 2010; 15(8):793-5.
View in:
PubMed
Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer. 2009 Nov 15; 115(22):5166-74.
View in:
PubMed
Factors influencing changes in employment among women with newly diagnosed breast cancer. Cancer. 2009 Jun 15; 115(12):2775-82.
View in:
PubMed
Breast cancer testing strategies and the utilization of targeted therapies: Data from the real world. J Clin Oncol. 2009 May 20; 27(15_suppl):e17518.
View in:
PubMed
Admissions for chemotherapy-related serious adverse effects (CR-SAEs) and rates of mortality among community cancer center patients. J Clin Oncol. 2009 May 20; 27(15_suppl):6571.
View in:
PubMed
Identifying high-priority quality measures for breast cancer quality improvement using data from a nationally representative sample. J Clin Oncol. 2009 May 20; 27(15_suppl):6507.
View in:
PubMed
Disparities in breast cancer adjuvant chemotherapy: moving beyond yes or no. J Clin Oncol. 2009 May 01; 27(13):2120-1.
View in:
PubMed
Breast biopsy patterns and outcomes in Surveillance, Epidemiology, and End Results-Medicare data. Cancer. 2009 Feb 15; 115(4):716-24.
View in:
PubMed
Behavioral health services for women who have breast cancer. J Clin Oncol. 2009 Feb 10; 27(5):706-12.
View in:
PubMed
Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer. J Clin Oncol. 2008 Dec 01; 26(34):5553-60.
View in:
PubMed
Selecting high priority quality measures for breast cancer quality improvement. Med Care. 2008 Aug; 46(8):762-70.
View in:
PubMed
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006 Aug 16; 98(16):1108-17.
View in:
PubMed
Chemotherapy-related serious adverse events and health care expenditures among commercially insured women with breast cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):6000.
View in:
PubMed
Psychosis associated with hypopituitarism. Gen Hosp Psychiatry. 1998 Jul; 20(4):248-54.
View in:
PubMed
Pathophysiology of congenital diaphragmatic hernia. XVI: Elevated pulmonary collagen in the lamb model of congenital diaphragmatic hernia. J Pediatr Surg. 1995 Aug; 30(8):1191-4.
View in:
PubMed